Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) The post Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting appeared first on Bio Tech Winners ..read more

Communiqué de presse The post PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas appeared first on Bio Tech Winners ..read more

Press release The post PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers appeared first on Bio Tech Winners ..read more

Ad-hoc-Mitteilung gemäss Art. 53 KR The post Santhera gibt vorläufige ungeprüfte Jahresergebnisse 2023 und ein Business-Update bekannt, gefolgt von der Publikation des Jahresberichts im Mai appeared first on Bio Tech Winners ..read more

Ad hoc announcement pursuant to Art. 53 LR The post Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May appeared first on Bio Tech Winners ..read more

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced ..read more

-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- The post Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 appeared first on Bio Tech Winners ..read more

SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. The post NKGen Biotech Announces Upcoming Publication at the 2024 American ..read more

Une conférence téléphonique et un webcast sont prévus ce jeudi 25 avril 2024 à 14 h CEST / 8 h EDT. The post NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L’ANNÉE 2023 appeared first on Bio Tech Winners ..read more

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. The post BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Mee ..read more